Abstract

    Open Access Case Report Article ID: ANPC-7-156

    Can newborn screening be cost benefit procedure if preventing serious complications of cystic fibrosis?

    Mirna Šubat-Dežulović, Gordana Pelčić*, Ana Valković, Sanja Flajšman-Raspor, Goran Pelčić and Anamarija Gjuran Coha

    Cystic Fibrosis (CF) is a common inherited disease with reported mean prevalence of 0.737/10,000 in 27 EU countries (Farrell J Cyst Fibros. 2008). Still, many EU countries have not implemented CF in the Newborn Screening (NBS) programme, including our country.  We report the case of a 7-month-old boy whose presenting signs of CF were life-threatening neurological symptoms caused by severe metabolic alkalosis and hypoelectrolytemia. By presenting this case, we argue hoping to persuade the authorities in any country that the available newborn screening for CF is the cost benefit procedure in preventing life treating consequences with the obvious impact on the long-term prognosis of this chronic disease. 

    Keywords:

    Published on: Dec 3, 2021 Pages: 20-23

    Full Text PDF Full Text HTML DOI: 10.17352/2581-4265.000056
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Indexing/Archiving

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on ANPC

    Google Reviews 11